SG11201609993YA - Treatment of immune disorders - Google Patents

Treatment of immune disorders

Info

Publication number
SG11201609993YA
SG11201609993YA SG11201609993YA SG11201609993YA SG11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA
Authority
SG
Singapore
Prior art keywords
treatment
immune disorders
immune
disorders
Prior art date
Application number
SG11201609993YA
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Internat Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by Mesoblast Internat Sàrl filed Critical Mesoblast Internat Sàrl
Publication of SG11201609993YA publication Critical patent/SG11201609993YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
SG11201609993YA 2014-06-10 2015-06-01 Treatment of immune disorders SG11201609993YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Publications (1)

Publication Number Publication Date
SG11201609993YA true SG11201609993YA (en) 2016-12-29

Family

ID=53385603

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609993YA SG11201609993YA (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Country Status (10)

Country Link
US (3) US10624930B2 (en)
EP (2) EP3154565B1 (en)
JP (4) JP6800757B2 (en)
KR (2) KR20170007854A (en)
CN (2) CN106659743B (en)
AU (2) AU2015273799B2 (en)
CA (1) CA2950804C (en)
HK (1) HK1231386A1 (en)
SG (1) SG11201609993YA (en)
WO (1) WO2015189063A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162754A1 (en) * 2011-06-03 2012-12-06 Mesoblast, Inc Methods of treating or preventing neurological diseases
AU2015273799B2 (en) 2014-06-10 2020-07-02 Mesoblast International Sarl Treatment of immune disorders
CN106929474B (en) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 M2 macrophage inducer
WO2018183825A1 (en) 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
JP7387603B2 (en) * 2017-11-29 2023-11-28 フィジーン、エルエルシー Interaction of fibroblasts and immune cells and their use for activation
CN112007165B (en) * 2020-08-27 2021-10-08 北京大学人民医院 Macrophage polarization regulator and application thereof in promoting thrombopoiesis
WO2024121819A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating inflammation with cellular compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
ES2645012T3 (en) * 2004-09-24 2017-12-01 Mesoblast, Inc. Method to enhance the proliferation and / or survival of mesenchymal precursor cells (MPC)
EP2399991B1 (en) 2005-04-12 2017-09-27 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
RU2562154C2 (en) * 2008-11-19 2015-09-10 Антродженезис Корпорейшн Amniotic adhesive cells
JP5678360B2 (en) * 2009-09-28 2015-03-04 株式会社ジーシー Method for culturing mesenchymal stem cells
WO2012051210A2 (en) * 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
CN108478599B (en) * 2011-11-30 2022-08-02 安斯泰来再生医药协会 Mesenchymal stromal cells and uses related thereto
CN102899293A (en) * 2012-11-01 2013-01-30 上海市肺科医院 Mesenchymal stem cells genetically modified with angiopoietin 1 gene and construction method and application thereof
EP4137560A1 (en) * 2014-04-07 2023-02-22 Mesoblast International Sàrl Improved stem cell composition
AU2015273799B2 (en) 2014-06-10 2020-07-02 Mesoblast International Sarl Treatment of immune disorders

Also Published As

Publication number Publication date
JP7279212B2 (en) 2023-05-22
CN114129598A (en) 2022-03-04
KR20170007854A (en) 2017-01-20
HK1231386A1 (en) 2017-12-22
AU2015273799B2 (en) 2020-07-02
JP2022040254A (en) 2022-03-10
US20200281984A1 (en) 2020-09-10
US20230141347A1 (en) 2023-05-11
US10624930B2 (en) 2020-04-21
JP2021028337A (en) 2021-02-25
AU2020244403B2 (en) 2024-03-07
US20170106023A1 (en) 2017-04-20
WO2015189063A1 (en) 2015-12-17
JP2023090901A (en) 2023-06-29
CN106659743B (en) 2022-03-01
JP2017526619A (en) 2017-09-14
JP7009594B2 (en) 2022-02-10
JP6800757B2 (en) 2020-12-16
AU2015273799A1 (en) 2016-12-15
EP4137146A1 (en) 2023-02-22
CA2950804A1 (en) 2015-12-17
EP3154565A1 (en) 2017-04-19
EP3154565B1 (en) 2023-05-03
US11406669B2 (en) 2022-08-09
KR20230038590A (en) 2023-03-20
CN106659743A (en) 2017-05-10
AU2020244403A1 (en) 2020-10-29
CA2950804C (en) 2023-08-22

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of pemphigus
IL285151A (en) Methods of treating fgf21-associated disorders
GB201701673D0 (en) Methods of well treatment
IL285003A (en) Treatment of joint conditions
SG11201609652RA (en) Treatment of polybacterials infections
HK1231386A1 (en) Treatment of immune disorders
GB201410116D0 (en) Method of treatment
HK1244711A1 (en) Treatment of hmgb1-mediated inflammation
GB201408387D0 (en) Treatment of respiratory disorders
IL253028B (en) Method of treatment
GB201416832D0 (en) Methods of treatment
GB201412578D0 (en) Treatment of neurological diseases
GB201408297D0 (en) Treatment of cancer
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11201702700UA (en) Methods for the treatment of peri-implantitis
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201512139D0 (en) Methods of treatment
AU2014902194A0 (en) Treatment of immune disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
AU2014902257A0 (en) Treatment of immune disorders 2
PT3851537T (en) Treatment of hyperbilirubinemia
GB201414023D0 (en) Treatment of autoimmune diseases
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment